Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422781 · ClinicalTrials.gov registry record · Phase 1
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
A Phase 1 study, sponsored by Immunomic Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05422781 is a Phase 1 study that has completed, run by Immunomic Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05422781, a Phase 1 study, has completed, sponsored by Immunomic Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).
Interventions
- DRUG ITI-3000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2023-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05422781
The ClinicalTrials.gov registry entry for NCT05422781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunomic Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ITI-3000 is the first listed.
NCT05422781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05422781 about?
NCT05422781 is a clinical study titled "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)". This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).
What is the current status of trial NCT05422781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-06-13. Estimated completion is 2023-06-27.
What interventions are being tested in trial NCT05422781?
The interventions under investigation include: ITI-3000 (DRUG).
Who is sponsoring clinical trial NCT05422781?
This trial is sponsored by Immunomic Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.